Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

NCT03020082 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: Danoprevir
DRUG: Ritonavir
DRUG: peginterferon alfa-2a
DRUG: RBV

Sponsor

Ascletis Pharmaceuticals Co., Ltd.